Schott Pharma AG KGaAFRA:1SX +0.50%67 ROE % is 13.25% as of Mar. 2026, which is 40% below its 10-year median of 22.01. GuruFocus rates FRA:1SX with a GF Score™ of 67/100 and a GF Value™ of €6.49. The stock has 2 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 87.33% on this metric.
The historical rank and industry rank for Schott Pharma AG KGaA's ROE % or its related term are showing as below:
FRA:1SX'
s ROE % Range Over the Past 10 Years
Min: 16.05 Med: 22.01 Max: 27.51
Current: 16.05
During the past 6 years, Schott Pharma AG KGaA's highest ROE % was 27.51%. The lowest was 16.05%. And the median was 22.01%.
FRA:1SX's ROE % is ranked better than 87.33% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs FRA:1SX: 16.05
Schott Pharma AG KGaA (FRA:1SX) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's ROE % distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Schott Pharma AG KGaA (FRA:1SX) has a ROE % of 13.25% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Schott Pharma AG KGaA and its competitors. This is 40% below median its historical median of 22.01. Over the past decade, Schott Pharma AG KGaA's ROE % has ranged from 16.05 to 27.51. According to the industry distribution chart, Schott Pharma AG KGaA ranks #101 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 12.7%.
Is Schott Pharma AG KGaA's ROE % too high?
Schott Pharma AG KGaA's current ROE % of 13.25% is 40% below median its 10-year median of 22.01. Over the past 10 years, this metric has ranged from a low of 16.05 to a high of 27.51. The Medical Devices & Instruments industry median ROE % is 2.40. Schott Pharma AG KGaA's value of 13.25% is 452.1% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #101 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #101 out of 797 companies for ROE %. This places Schott Pharma AG KGaA in the top 13% of its industry — outperforming the majority of peers. The industry median ROE % is 2.40. Schott Pharma AG KGaA's value of 13.25% is 452.1% above this benchmark. Historically, Schott Pharma AG KGaA's own ROE % has ranged from 16.05 to 27.51 over the past decade. While the company's 10-year median is 22.01 vs. the industry median of 2.40, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current ROE % of 13.25% is 452.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current ROE % is 13.25%, which is 40% below median its own 10-year median of 22.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (FRA:1SX) has a current ROE % of 13.25%. The stock's GF Value™ is €6.49, compared to a current price of €4.06 — trading 37.4% below its estimated fair value. The current ROE % is 13.25%, which is 40% below median its 10-year median of 22.01 and 452.1% above the Medical Devices & Instruments industry median of 2.40. Schott Pharma AG KGaA's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Schott Pharma AG KGaA (FRA:1SX), the current ROE % is 13.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (FRA:1SX) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €4.06 is trading 37.4% below its estimated GF Value™ of €6.49.
Key valuation signals for FRA:1SX:
ROE %: 13.25% (40% below median its 10-year median of 22.01)
GF Value™: €6.49 vs. price of €4.06 (37.4% below fair value)
Industry Position: 452.1% above the Medical Devices & Instruments median (#101 of 797)
No single metric tells the full story. See the FRA:1SX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
67GF Score
Get the complete analysis for FRA:1SX
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1SX has been successfully added to your 
